NEW YORK, NEW YORK, UNITED STATES, September 9, 2020 /EINPresswire.com/ — Manhattan BioSolutions, a biotechnology company focused on the discovery of the next-generation therapies for the treatment of cancer and inflammatory diseases, has been awarded a Phase I SBIR grant by the National Science Foundation (NSF) entitled “Genetically Engineered BCG […]
Uncategorized
19 posts
New York, NY August 25, 2020—EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a strategic research collaboration with Manhattan BioSolutions, Inc., a biotechnology company focused on developing next-generation therapies for cancer and inflammatory diseases. Through the collaboration, the companies will jointly discover differentiated antibody therapeutics for […]
New York, NY, May 27, 2020 – Manhattan BioSolutions, Inc. (MBS), a biotechnology company focused on the discovery of the next-generation therapies for the treatment or prevention of cancer, today announced that the company has entered into an agreement with the Research Foundation for the State University of New York, […]
San Diego, CA, May 12, 2020—Nascent Biotech, Inc (OTCQB: NBIO), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat cancers and viral infections, and Manhattan BioSolutions, Inc., a biotechnology company focused on the discovery of the next-generation therapies for the treatment of cancer and inflammatory diseases, today announced […]
https://projectreporter.nih.gov/project_info_description.cfm?aid=9623199&icde=51409496&ddparam=&ddvalue=&ddsub=&cr=1&csb=default&cs=ASC&pball= Project Number: 1R43CA228746-01A1 Title: NOVEL RECOMBINANT BCG FOR IMMUNOTHERAPY OF BLADDER CANCER
https://jlabs.jnjinnovation.com/quickfire-challenges/jlabs-nyc-quickfire-challenge#paragraph-5131 https://www.prnewswire.com/news-releases/johnson–johnson-innovation-opens-jlabs–nyc-in-collaboration-with-new-york-state-and-the-new-york-genome-center-300670313.html
